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Abstract 
 
Lung ultrasound is a useful tool for the assessment of patients with both acute and chronic heart 
failure. The use of different image acquisition methods, inconsistent reporting of the technique 
employed and variable quantification of “B-lines”, however, have all made it difficult to compare 
published reports.  As a result, strategies to improve patient care by its use have been difficult to 
develop. There is a need to ensure future studies utilizing lung ultrasound in the assessment of 
heart failure adopt a standardized approach to reporting the quantification of pulmonary 
congestion. This consensus report includes a checklist to provide standardization in the 
preparation, review and analysis of manuscripts. This will serve as a guide for investigators and 
clinicians and enhance the quality and transparency of lung ultrasound research. Key aspects of 
standardization discussed include equipment used, number of chest zones assessed, the 
method of quantifying B-lines, the presence and timing of additional investigations (e.g., 
natriuretic peptides and echocardiography) and the impact of therapy.  
 
Keywords: lung ultrasound, heart failure, methodology, reporting checklist 
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Introduction 
Pulmonary congestion is one of the most important findings in heart failure (HF), yet traditional 
methods, e.g., clinical examination and chest x-ray, are relatively insensitive for its detection.1-3 
Lately, there has been tremendous growth in the use of lung ultrasound (LUS) for the detection 
of pulmonary congestion in HF both in research and, more recently, in clinical practice.2,4-10 LUS 
has been proposed as a useful tool in the assessment of patients with both acute and chronic 
HF.2,5,8,10 This technique enables the detection of pulmonary congestion in patients presenting 
with acute dyspnea with higher accuracy than chest auscultation or chest x-ray.5 The LUS 
findings of pulmonary congestion, commonly called B-lines, change dynamically with treatment 
for acute HF and can provide prognostic information in both acute and chronic HF.11,12 However, 
different methods and inconsistent reporting of the LUS technique used and the quantification of 
B-lines make it difficult to compare existing studies. This lack of standardization impedes the 
development of strategies to reduce pulmonary congestion and improve patient care.11 One 
prior international consensus statement described a wide variety of LUS applications, but was 
not specifically focused on its use in HF or detailed in its description of the methodological 
aspects.4 With the anticipated growth in the use of LUS, and in subsequent potential 
publications, in patients with HF, there is a need to develop a standardized reporting guide for 
the quantification of pulmonary congestion by LUS in HF.  
 
Methods and Aims 
Our aim was to create a checklist to enhance the quality and transparency of LUS research and 
reporting. This consensus statement is intended to serve as a guide for investigators, reviewers, 
editors and readers in the preparation, evaluation and interpretation of manuscripts involving the 
use of LUS in HF.13 We convened a group of cardiologists and emergency physicians with 
expertise in LUS, HF, epidemiological studies, and clinical trials to review the current literature 
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in this area.  Following discussion and agreement, they composed a succinct evidence-based 
reporting checklist. In contrast to other existing guidelines, we focused on unique aspects of 
LUS research, including study design and image analysis. 
 
Reporting Checklist 
Title, abstract and study design 
All reports should follow previously published guidelines regarding the use of a structured 
abstract and appropriate title.14 The relevant guidelines for the design of the study e.g. 
observational vs. randomized clinical trial should be used.14 For diagnostic studies, the 
reference standard should be clearly described and for prognostic studies, authors should report 
how the primary outcome was adjudicated, as applicable.15 A description of the key aspects of 
both the general study design and LUS-specific components is provided in the reporting 
checklist (Table 1 and Figure 1). 
 
Participant characteristics, co-morbidities and study setting 
In studies of patients with known or suspected HF, the definition of HF used should be 
described in detail and should be consistent with recognized definitions.16,17  Standard patient 
descriptors should be reported as should how and where the patients were recruited and 
whether any inclusion and exclusion criteria were applied. Reported patient characteristics 
should include general demographics, such as age, sex, and body mass index, vital signs 
including respiratory rate, blood pressure and heart rate, as well as important comorbidities, 
symptoms and signs of heart failure, measures of cardiac function and natriuretic peptides.  
Diffuse B-lines, which usually reflect pulmonary congestion, can also be detected by LUS in 
other conditions such as pulmonary contusions, adult respiratory distress syndrome (ARDS), 
and interstitial lung disease.18-22 Pulmonary congestion can also result from conditions other 
than HF, e.g. end stage renal disease. Consequently, it is essential that studies designed to 
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detect potential pulmonary congestion in patients with suspected or established HF also make a 
statement about the presence or absence of these other co-morbidities known to lead to B-lines 
on LUS (Table 1).11 Without a clear description of these variables, study results may be 
confounded or misleading. If these conditions are exclusion criteria, this should be clearly stated 
in the Methods section of the study. If patients having one of these conditions have been 
included, their potential significance must be evaluated, e.g. by undertaking stratified, sensitivity 
and other analyses to determine whether they have confounded the interpretation of potential 
pulmonary congestion and change in congestion over time and/or in response to treatment. 
Reporting of the setting of the study (e.g. pre-hospital, ambulatory care, emergency department, 
hospital ward, intensive care unit) is also important, as HF patients will demonstrate a different 
spectrum of B-lines reflecting the likely degree of pulmonary congestion in each setting and 
interpretation and comparison of studies must thus take study setting into account (Figures 1 
and 2).5,11,23 
 
Ultrasound equipment, image acquisition and image analysis 
The manufacturer and model of the ultrasound equipment used should be described. The type 
of transducer, transducer orientation (transverse vs. sagittal) and clip duration (which may be 
limited to shorter time periods on pocket ultrasound devices) can alter the number of detectable 
B-lines in patients with HF.24,25 Specifically, phased array transducers (as compared to 
curvilinear transducers) and longer clip duration (6-7 seconds/video clip) allow for observation of 
a higher number of B-lines in HF.24,25 Similarly, patient positioning during the LUS should be 
described and ideally performed in a standardized position due to its effect on B-line count, as 
patients with acute HF may have a higher number of B-lines in the supine vs. the sitting 
postion.26  
The number and location of chest zones examined should be clearly described. Prior studies in 
HF cohorts have reported 4 to 28 chest zones (Table 2), and in 2012 an international guideline 
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recommended either the use of 8 or 28 zones (Figure 3A).4 Different approaches have since 
been described e.g. using 6 zones in the assessment of dyspneic patients in the emergency 
department and without apparent loss of diagnostic accuracy.4,5 Based on the currently 
available data, we suggest that at least 3 zones on each hemithorax (6 zones total; Figure 3B) 
should be examined and the B-line number reported in patients with HF.5 
 
For B-line quantification, two general approaches have been reported in HF cohorts (Table 2):  
1) A count-based method, in which the sum of B-lines in one intercostal space per zone 
across all zones is reported.10,23   
2) A scoring system, in which a minimum number of B-lines in one intercostal space per 
zone is used to define a zone as “positive”. Positive zones are then summed to delineate 
a cut-off value. For example, ≥3 B-lines in 2 zones on each hemithorax are consistent 
with a diagnosis of pulmonary edema in dyspneic patients presenting to the emergency 
department.5,27,28  
 
If software is used to quantify the number of B-lines, the manufacturer and version of the 
software should be reported, as the type of software could potentially contribute to variability in 
B-line number between vendors. In addition, the cut-off definition process or decision limits for 
the detection of HF should be accurately described, if applicable.  As large pleural effusions 
may interfere with B-line quantification, the presence of pleural effusions (overall frequency of 
unilateral or bilateral pleural effusions) and how pleural effusions were assessed should be 
reported, when possible. 
 
Blinding & central image interpretation 
Blinding is an important methodologic feature in diagnostic and prognostic studies to minimize 
bias and maximize the validity of results. Sonographer knowledge of the findings on clinical 
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examination or results of other diagnostic modalities, therapies and medical history, should be 
described when reporting image acquisition. Blinding to these same aspects should be reported 
with respect to the individuals undertaking B-line quantification. The temporal aspects of 
blinding should be described for studies involving serial LUS examinations. Although HF studies 
investigating the impact of reader experience on both real-time and offline quantification of B-
lines have demonstrated similar results between novice and expert readers, with high inter-
reader agreement, the experience of the personnel involved in analyses and the setting in which 
the analyses are performed should be reported.25,29 Specifically, whether the LUS images were 
interpreted in real-time (at the bedside), off-line by investigators not involved in the image 
acquisition, or at a central core laboratory should be reported. In order to obtain unbiased 
results, blinded reading in a central core laboratory clearly is preferable.   
 
Additional investigations  
The results of additional investigations assessing hemodynamic or clinical congestion, such as 
chest radiography, echocardiography, invasive hemodynamic measurements or natriuretic 
peptide levels, should be documented. Importantly, the temporal relationship between these 
investigations and the assessment of pulmonary congestion by LUS should be reported. This 
information will also facilitate a better understanding of the sequence of the dynamic changes of 
these congestion markers.30 For example, whether the chest radiograph was performed at the 
same time as the LUS study or whether it was performed 24 hours later affects the 
interpretation of the relationship between these investigations. Similarly, the initiation of any 
therapy directed at congestion, and any response that occurred between the LUS study and 
supporting investigations should be clearly documented (e.g. if pulmonary artery pressures were 
measured, after which the patient received diuretics, followed by the LUS study, should be 
documented).  
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Data reporting and analysis 
Sonographic B-lines in patients with HF are known to be differentially distributed.12,31 As a 
higher prevalence of B-lines occurs in more dependent chest zones, the reporting of missing 
data in zones that could not be analyzed (e.g., due to cardiomegaly or large pleural effusions) is 
essential. More dependent zones are also those most likely influenced by the presence of 
pleural effusions or, in the left hemithorax, by cardiomegaly. The method or methods used to 
deal with missing B-line data or missing zones should be clearly described.  
Statistical methods appropriate for the quantification method (e.g. score or count data) should 
be used and detailed in the statistical analysis section. As B-lines are frequently not normally 
distributed, the analysis should consider their distribution among the patients studied.  
   
Results and discussion 
The presentation of results should include the number of patients enrolled and excluded from 
analysis or follow-up, the proportion with adequate images and the number analyzed. Authors 
should provide reasons for non-participation at each stage, preferably using a CONSORT flow 
diagram for illustration.32 The LUS data description should include the number and variation of 
B-lines at baseline and at follow up, if applicable. In addition to the main study results, sources 
of potential bias and the generalizability of study findings should be discussed, as well as any 
implications for clinical practice with respect to the role of LUS.  
 
Gaps in current knowledge 
While there is general agreement on how to diagnose pulmonary edema with LUS in patients 
with undifferentiated dyspnea presenting to the emergency department, the wide range of LUS 
methods used, has made the establishment of a standardized approach and cut-off values in 
other settings challenging. This hampers the performance of meta-analyses of available 
evidence and consequently the genesis of a widely accepted consensus. Studies with larger 
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sample sizes comparing different imaging protocols with respect to the number of zones and B-
line quantification method, in both ambulatory and hospitalized HF patients, including on 
admission and pre-discharge, would be useful to inform clinical guidelines and future clinical 
trials. Specifically, whether LUS provides incremental diagnostic or prognostic information 
beyond current methods in patients with suspected or known HF should be further addressed 
through well-designed, prospective investigations, with appropriate statistical analyses, e.g. 
including comprehensive multivariable models incorporating other important diagnostic and 
prognostic variables. In addition, studies investigating treatment response and the adequacy of 
decongestive therapy, for instance at the time of hospital discharge in large, well-defined HF 
cohorts will be important. Specifically, outcome randomized controlled trials assigning patients 
to a treatment intervention designed to maximize B-line resolution vs. standard of care could 
inform clinical practice in the future. Similarly, the value and frequency of LUS use during 
outpatient clinic follow up warrants further investigation. While B-lines can be detected 
irrespective of ejection fraction in both ambulatory and hospitalized patients with heart failure, 
recent reports  in patients with reduced vs. preserved ejection fraction demonstrated differing 
results with respect to the number of B-lines in these HF cohorts23,33 These findings could be 
due to different degrees of pulmonary congestion or other confounders. Further research is 
needed to better understand the impact of these factors on LUS findings in patients with HF and 
how to best integrate LUS in the management of these patients. 
 
Conclusions 
Lung ultrasound can provide useful information regarding the presence and degree of 
pulmonary congestion in patients with heart failure. Consistent reporting of certain 
methodological aspects should be considered in studies employing lung ultrasound in heart 
failure populations to assure high-quality research result dissemination and allow for future 
standardization.  
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Table 1. Reporting checklist for lung ultrasound studies in heart failure cohorts 
 
 No. Aspects for consideration Literature 
Title or 
abstract 
1 Identification as a study employing lung ultrasound as a 
measure of pulmonary congestion 
 
Abstract 2 Structured summary of study design, methods, results, and 
conclusions 
 
Introduction 3 Scientific and clinical background, including the intended 
use and clinical role of lung ultrasound 
 
 4 Study hypothesis and objectives   
Methods    
Study design 5 Whether data collection was planned before the lung 
ultrasound was performed (prospective study) or after 
(retrospective study) 
 
 6 Description of how heart failure was defined 16,17 
 7 Description of reference standard for the primary outcome 
and how it was adjudicated (if applicable) 
15 
Participants 8 Inclusion and exclusion criteria with particular attention to 
factors that could confound lung ultrasound findings (e.g. 
interstitial lung disease, pneumonitis, ARDS, dialysis) 
18-22 
 9 On what basis potentially eligible participants were 
identified (such as symptoms, results from previous tests, 
inclusion in registry) 
 
 10 Where and when potentially eligible participants were 
identified (setting, location and dates) 
5,11,23 
Study size 11 Explain how the study size was arrived at  
Lung 
ultrasound 
method 
12 Type of ultrasound equipment used (such as high-end 
ultrasound system or pocket size ultrasound device), 
including type and orientation (transverse vs. sagittal) of 
transducer 
24,25 
 13 Patient positioning during lung ultrasound examination 26 
 14 Number and location of lung ultrasound zones examined 5,6,8,11,28 
 15 Duration of recorded lung ultrasound clips (if image 
analysis was performed offline) 
24,25 
 16 Whether clinical information was available to the 
performers of the lung ultrasound 
 
Lung 
ultrasound 
image 
analysis 
17 Whether clinical information was available to the readers of 
the lung ultrasound (image analysis blindly performed 
offline vs. real time) 
 
 18 For serial lung ultrasound assessment: Whether the timing 
of the lung ultrasound was available to the readers 
(temporal blinding) 
11 
 19 Method of B-line quantification (e.g. sum of all B-lines 
across all lung zones, or score based on B-line number in a 
given zone), including inter- and intra-observer variability. If 
automated software was used, type and version of 
software. 
4,11 
 20 Describe how pleural effusions were assessed by  
18 
 
ultrasound and report the number of patients with unilateral 
or bilateral pleural effusions on ultrasound. 
Additional 
investigations 
21 Describe any additional investigations supporting the 
diagnosis or degree of congestion (e.g. echocardiography, 
natriuretic peptides, invasive hemodynamics) performed 
and their temporal relationship to the LUS examination, as 
well as to therapy targeted at congestion. 
 
Data analysis 22 Number of patients with missing LUS zones & how these 
patients were handled in the analysis. How lung ultrasound 
zones with pleural effusions that interfered with B-line 
quantification were handled in the analysis. 
 
Results 23 Report the number of patients enrolled, excluded, patients 
with adequate images and those analyzed, as well as 
outcomes. Give reasons for non-participation at each 
stage. Consider using a flow diagram. 
 
 24 Baseline demographic and clinical characteristics of 
participants 
 
 25 Number and variation of B-lines at baseline (and follow up, 
if applicable) 
 
Discussion 26 Study limitations, including sources of potential bias, 
statistical uncertainty, and generalizability 
 
 27 Implications for clinical practice, including the intended use 
and clinical role of lung ultrasound 
 
Other 
information 
28 Name of registry and registration number if applicable.  
 29 Sources of funding and other support; role of funders  
 
 
Legend: 
Lung ultrasound-specific aspects are highlighted in light blue. 
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Table 2. Overview of common B-line quantification methods in patients with heart failure 
 
Zones, 
n 
Location of zones Method B-line quantification Sample 
studies 
28 Anterior & lateral chest Count Sum of B-lines in all zones 8,9,34,35 
Score Mild: 6-15 B-lines in all zones 
Moderate: 16-30 B-lines in all zones 
Severe: >30 B-lines in all zones 
7,8 
11 Anterior & lateral chest Score 0 points: <3 B-lines per zone 
1 point: ≥3 B-lines per zone 
Score: Number of points 
31 
8 Anterior & lateral chest Count Sum of B-lines in all zones 8,10,23 
Score 0 points: <3 B-lines per zone 
1 point: ≥3 B-lines per zone 
Score: Number of points 
8,9,27,28 
6 Anterior & lateral chest Score 0 points: <3 B-lines per zone 
1 point: ≥3 B-lines per zone 
Score: Number of points 
5 
5 Anterior & posterior chest Count Sum of B-lines in all zones 6 
Score 0 points: ≤3 B-lines per zone 
1 point: >3 B-lines per zone 
Score: Number of points 
6 
4 Anterior & lateral chest Score 0 points: <3 B-lines per zone 
1 point: ≥3 B-lines per zone 
Score: Number of points 
36 
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Figure 1. Overview of important methodological aspects in the quantification of 
pulmonary congestion by lung ultrasound in heart failure 
 
Legend: 
HF: heart failure, ED: emergency department, ESRD: end-stage renal disease 
* Outcome measures could represent B-line count/score, a diagnosis or prognostically important 
event(s). 
 
Figure 2. Practical aspects of lung ultrasound in heart failure cohorts 
 
 
Legend: 
HF: heart failure, LUS: lung ultrasound 
 
Figure 3. Example of 8 and 6 chest zones for lung ultrasound imaging 
 
Legend: 
Adapted from: Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic 
changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic 
heart failure: a systematic review. Eur J Heart Fail. 2017;19(9):1154-1163. 
Type of HF cohort: 
Pre-hospital 
ED 
In-hospital 
Outpatient 
Imaging protocol: 
• Equipment used 
• Number & location of zones 
• Duration of ultrasound clip 
• Patient positioning 
Blinding of  
sonographers: 
• Clinical information 
Comorbidities 
(e.g. pulmonary fibrosis, ESRD) 
Image analysis: 
• B-line quantification method 
(e.g. count, score) 
Data analysis: 
• Distribution of B-lines 
• Missing zones  
(e.g. due to pleural effusions) 
Blinding of readers: 
• Clinical information 
• Temporal blinding 
Additional investigations: 
(e.g. natriuretic peptides, other 
imaging studies)  
• Timing in relation to  
lung ultrasound & HF therapy 
Outcome 
measure* 
Guideline-based assessment: 
• Pre-defined criteria 
• Adjudication, if applicable 
HF Patients 
- Co-morbidities 
- Setting (e.g. outpatient) 
LUS Image Acquisition 
- Type of ultrasound system & transducer 
- Transducer orientation 
- Patient positioning 
- Number & location of LUS zones 
- LUS clip duration 
LUS Image Analysis 
- Offline vs. real time analysis 
- Blinding of readers (to which aspects?) 
- Method of B-line quantification 
- Frequency of pleural effusions 
Data Analysis 
- Number of patients with missing LUS zones 
- Number and variation of B-lines 
1 
2 3 
4 
A)         8 zone method B)        6 zone method 
